Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

By afschroeder • June 26, 2026

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee JK. Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. J Clin Invest. 2026 Jun 23:e200438. doi: 10.1172/JCI200438. Epub ahead of print. PMID: 42348027.

Tags: cancer immunotherapy, Drug screens, Hematology/Oncology, Immunology, oncology, prostate cancer, Publications

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar[...]

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin[...]

The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy

Markosian C, Schiller GJ. The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy. Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03023-z. Epub[...]